Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 585-590

  Hotte, Sébastien J ^a   Winquist, Eric W ^a   Lamont, Elizabeth ^a   MacKenzie, Mary ^a   Vokes, Everett ^a   Chen, Eric X ^a   Brown, Shirley ^a   Pond, Gregory R ^a   Murgo, Anthony ^a   Siu, Lillian L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; SALIVARY GLAND CARCINOMA; SIDE EFFECT; VOMITING; BIOSYNTHESIS; GENETICS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SALIVARY GLAND TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20044384866     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.125     Document Type: Article

References (20)

1. Sessions RB, Harrison LB, Forastiere A: Tumors of the salivary glands and paragangliomas, in Devita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven Publishers, 2000
2. Tannock IF, Sutherland DJ: Chemotherapy for adenocystic carcinoma. Cancer 46:452-454, 1980
3. Vermorken JB, Verweij J, de Mulder PH, et al: Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 4:785-788, 1993
4. Verweij J, de Mulder PH, de Graeff A, et al: Phase II study on mitoxantrone in adenoid cystic carcinoma of the head and neck. Ann Oncol 7:867-869, 1996
5. Hill ME, Constenla DO, A'Hern RP, et al: Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33:275-278, 1997
6. Airoldi M, Fornari G, Pedani F, et al: Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20:3781-3784, 2000
7. Airoldi M, Pedani F, Succo G, et al: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541-547, 2001
8. Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25:571-576, 2001
9. Jeng YM, Lin CY, Hsu HC: Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma. Cancer Lett 154:107-111, 2000
10. Krystal GW, Honsawek S, Kiewlich D, et al: Indolamine tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668, 2001
11. Lev S, Blechman JM, Givol D, et al. Steel factor and c-kit proto-oncogene: Genetic lesson in signal transduction. Crit Rev Oncog 5:141-168, 1994
12. Holst VA, Marshall CE, Moskaluk CA, et al: KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956-960, 1999
13. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003
14. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
15. Sonia JC, Johnson BE, Chevalier TL: Imatinib in small cell lung cancer. Lung Cancer 41(suppl 1):S49-S53, 2003
16. Pardanani A, Elliott M, Reeder T, et al: Imatinib for systemic mast-cell disease. Lancet 362:535-536, 2003
17. Dagher R, Cohen M, Williams G, et al: Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038, 2002
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
20. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003